HAYWARD, Calif.--Lynx Therapeutics reached agreement on March 31 with Hoechst Marion Roussel and its affiliate Hoechst Schering AgrEvo to activate a subscription enabling AgrEvo to access a number of Lynx technologies. AgrEvo will pay a fee and minimum yearly subscription payments for Lynx's gene expression technologies, including Megaclone and its two derivatives, Megasort, and Massively Parallel Signature Sequencing (MPSS).
Megaclone allows simultaneous cloning of millions of DNA molecules or fragments in a sample and the parallel probing or assaying of resulting clones. Megasort is designed to extract from two related biological samples genes whose expressions differ between the samples. MPSS is designed to obtain 20 base signature sequences of nearly all genes expressed in a sample.
Lynx will receive $2 million from AgrEvo for non-exclusive access to the technologies, limited to the agricultural field. In addition, minimum subscription payments of $2 million per year will cover Lynx's costs plus profits for analyses to be performed by Lynx on behalf of AgrEvo. AgrEvo's subscription may be extended for up to three years beyond an initial one-year period.